DA Garrison, Y Jin, Z Talebi, S Hu, A Sparreboom… - Molecules, 2022 - mdpi.com
Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of
relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily eliminated via …